Whether ceritinib/ceritinib is already on the market in China and the purchase channels

Ceritinib/Ceritinib (Ceritinib) is an oral ALK inhibitor, mainly used to treat patients with ALK-positive non-small cell lung cancer (NSCLC). The drug inhibits the activity of ALK tyrosine kinase, thereby blocking the signaling pathways of cancer cells and inhibiting tumor proliferation. With the improvement of domestic medical standards and the introduction of targeted drugs, ceritinib has been officially launched in China, providing an important treatment option for ALK positive patients.

In the domestic market, ceritinib has been included in the medical insurance catalog, allowing patients to receive certain financial support. Patients can purchase the drug through formal channels in hospital pharmacies in various regions, but the specific price and medical insurance reimbursement ratio vary due to different regional policies. Therefore, patients should consult with the hospital pharmacy before taking medication to clarify the amount of self-pay and the scope of reimbursement by medical insurance, and arrange a reasonable treatment plan.

For some patients who want to obtain drugs through overseas channels, the generic version of ceritinib produced in Laos provides a lower-priced option. The price of each box of this generic drug is about more than 1,000 yuan, and the drug ingredients are basically the same as the domestic original drugs, which can ensure the therapeutic effect. Purchasing overseas generic drugs through formal channels can alleviate patients' financial pressure to a certain extent, but it is necessary to ensure that the source of drugs is legal and safe to avoid affecting the efficacy due to irregular channels.

In general, ceritinib is launched in China and included in medical insurance, providing a more accessible treatment option for patients with ALK positive non-small cell lung cancer. Patients can choose to purchase domestic original drugs or overseas generic drugs based on their own economic conditions, medical insurance policies and doctor's guidance. At the same time, efficacy and safety evaluations should be carried out regularly during medication to ensure that the therapeutic effect is maximized and potential risks are reduced.

Reference materials:https://www.drugs.com/